Investor Presentation

Shalby/SE/2026-27/69 November 03, 2026 The Listing Department Corporate Service Department National Stock Exchange of India Ltd BSE Limited Mumbai 400 051. Mumbai 400 001. Scrip Code : SHALBY Scrip Code: 540797 Through : https://neaps.nseindia.com/NEWLISTINGCORP/ Through : http://listing.bseindia.com Sub: Investor Presentation for the quarter ended 30th September 2026 Dear Sir / Madam, We are submitting herewith Investor Presentation on financial & operational performance of the Company for the Quarter ended September 30, 2026, which will be discussed at the Investor Conference call scheduled tomorrow i.e. on November 04, 2026 at 04:00 p.m. IST. The said Investor Presentation is being uploaded on website of our Company at https://www.shalby.org/investors/  Investors Presentation. You are requested to take the same on your record. Thanking you, Yours sincerely For Shalby Limited Dr. Vikram Shah Chairman and Managing Director DIN: 00011653 Encl.: Investor Presentation Investor Presentation Q2 & H1 FY2027 DISCLAIMER This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia,Japanoranyjurisdictionwheresuchdistributionisunlawful. ThispresentationhasbeenpreparedbyShalbyLimited(the"Company").Thesematerialsarenotforpublicationordistribution,directlyorindirectly,inorintotheUnitedStates(includingitsterritories and possessions, any state of the United States and the District of Columbia). These materials are not an offer of securities for sale into the United States, Canada or Japan or any other jurisdiction. Any securitiesoftheCompanyhavenotbeenandwillnotberegisteredundertheU.S.SecuritiesActof1933,asamended,andmaynotbeofferedorsoldintheUnitedStates,exceptpursuanttoanapplicable exemptionfromregistration.NopublicofferingofanysecuritiesoftheCompanyisbeingmadeintheUnitedStates. The information contained in this presentation is for information purposes only and does not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offertobuyorsubscribeforanysecurities,norshallitoranypartofitformthebasisoforbereliedoninconnectionwithanycontract,commitmentorinvestmentdecisioninrelationtheretoinIndia,the UnitedStatesoranyotherjurisdiction. No personaccepts anyliabilitywhatsoeverforanylosshowsoeverarisingfromthe use ofthisdocumentorofits contents orotherwisearisinginconnectiontherewith.Theinformationsetoutherein may be subjecttoupdating, completion,revision, verification andamendment withoutnoticeandsuchinformation maychange materially.Financialinformation containedinthispresentation hasbeenderived fromtherestatedconsolidatedandstandalonefinancialstatementsoftheCompanyandhavebeenroundedofftothenextinteger,exceptpercentageswhichhavebeenroundedofftoonedecimalpoint. This presentation contains certain "forwardlooking statements". Forward‐looking statements are based oncertain assumptions and expectations of future events.Actual future performance, outcomes and results maydiffermateriallyfromthoseexpressedinforward‐lookingstatementsasaresultof anumberofrisks, uncertaintiesandassumptions.AlthoughtheCompanybelievesthatsuchforward‐looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to updateforward-lookingstatementsortoadaptthemtofutureeventsordevelopments. This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information containedtherein has been obtainedfromsourcesbelievedtobereliable,butthereis noassurancethattheinformation is accurate or complete.Neitherthe Companynor anyof itsadvisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. No representation or claim is made that the results or projections contained inthis presentation will actually be achieved. Allindustry data and projections contained inthis presentation are based on data obtained fromthe sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentationforanypurpose.Noresponsibilityorliabilitywhatsoeverisundertakenforthecontentshereof. This presentation is based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developmentsmayaffecttheinformationcontainedinthispresentation,whichneithertheCompanynoritsadvisorsorrepresentativesareunderanobligationtoupdate,reviseoraffirm. AGENDA 0011 SSHHAALLBBYY GCORONSUOPLQIDUAATRETDERQLUYA ARNTDER ALNYN &U AMLID P-YEERAFRO RPMEARNFOCREMANCE 0022 HSHOASLPBITYA LS TBAUNSDINAELSOSN EQUQAURATRETRELRYL YA N&D M AIDN-NYUEAALR PPEERRFFOORRMMAANNCCEE SHALBY INTERNATIONAL QUARTERLY & MID-YEAR PERFORMANCE SHALBY MEDTECH QUARTERLY & MID-YEAR PERFORMANCE ABOUT SHALBY LIMITED Financials Snapshot Q2 FY27 Consolidated Total Revenue at ₹ 3,182 mn in Q2 FY27 vs ₹ 2,899 mn in Q2 FY26 Consolidated EBITDA at ₹ 464 mn in Q2 FY27 vs ₹ 461 mn in Q2 FY26 Consolidated Consolidated PBT at ₹ 165 mn in Q2 FY27 vs ₹ 191 mn in Q2 FY26 Financial Highlights Consolidated PAT at ₹ 79 mn in Q2 FY27 vs ₹ 73 mn in Q2 FY26 Consolidated Annualized ROCE stood at 6.6% Standalone Total Revenue at ₹ 2,506 mn in Q2 FY27 vs ₹ 2,298 mn in Q2 FY26 Standalone EBITDA at ₹ 457 mn in Q2 FY27 vs ₹ 448 mn in Q2 FY26 Standalone Standalone PBT at ₹ 316 mn in Q2 FY27 vs ₹ 306 mn in Q2 FY26 Financial Highlights Standalone PAT at ₹ 235 mn in Q2 FY27 vs ₹ 198 mn in Q2 FY26 Standalone Annualized ROCE stood at 9.4% Consolidated Performance Highlights – Q2 FY27 Financial Performance (in INR Mn) Total Revenue EBITDA1 & Margin 3386 3182 490 461 464 2899 15.9% 14.5% 14.6% Q2 FY26 Q1 FY27 Q2 FY27 Q2 FY26 Q1 FY27 Q2 FY27 Up 9.8% Up 0.8% PBT & Margin PAT & Margin 6.6% 5.8% 5.2% 2.5% 3.1% 2.5% Q2 FY26 Q1 FY27 Q2 FY27 Q2 FY26 Q1 FY27 Q2 FY27 Down13.7% Up8.3% 1. EBITDA includes other income Consolidated Performance Highlights – H1 FY27 Financial Performance (in INR Mn) Total Revenue EBITDA1 & Margin 6569 946 954 5933 15.9% 14.5% H1 FY26 H1 FY27 H1 FY26 H1 FY27 Up 10.7% Up 0.9% PBT & Margin PAT & Margin 417 150 7.0% 5.5% 2.5% 2.8% H1 FY26 H1 FY27 H1 FY26 H1 FY27 Down13.3% Up 22.9% 1. EBITDA includes other income Consolidated P/L & B/S – Q2 FY27 Profit & Loss Balance Sheet (INR Mn) Gross 5371 Q2 Q1 Q2 Q-o-Q Y-o-Y Particulars (INR Mn) Borrowings FY27 FY27 FY26 Growth Growth Total Revenue 3182 3386 2899 (6.0%) 9.8% Cash & Cash 789 Equivalents EBITDA2 464 490 461 (5.2%) 0.8% Net Cash/(Debt) (4582) EBITDA Margin % 14.6% 14.5% 15.9% PBT 165 197 191 (16.4%) (13.7%) Debt/Equity 0.45x PBT Margin % 5.2% 5.8% 6.6% ROCE1 6.6% PAT 79 105 73 (24.9%) 8.3% PAT Margins % 2.5% 3.1% 2.5% Notes: 1. ROCE= Annualized EBIT/ Average (Equity +Debt-Cash & Cash Equivalent) 2. EBITDA includes other income. Shalby Limited : Consolidated Revenue & EBITDA Breakup – Q2 FY27 Revenue (%) Revenue (in INR Mn) EBITDA (in INR Mn) Shalby Hospitals, 80.51% 2561.8 416.9 Pharma & Franchise Shalby International (PK Healthcare, 9.32% 37.7 296.7 Delhi-NCR) Shalby MedTech 9.93% 316.0 3.6 (Implant Business) Others 0.24% 7.7 6.2 Shalby Limited 100% 3182.2 464.4 (Consolidated) Notes: 1. Includes Shalby Academy, Slaney and Griffin which is into pharmacy trading 2.Includes fellow subsidiaries in Delhi-NCR region. Financial Trends – Shalby Limited (Consolidated) Total Revenue (In INR Crs) EBITDA (In INR Crs) & Margin (%) 1168 1115 827 159 160 711 132 22% 19% 19% 21% 14% 15% FY21 FY22 FY23 [Showing first 8,000 characters — download PDF for full document]